InSphero
InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cell interaction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors or primary cells to mimic structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland.
Tech Stack (30 technologies)
Frequently Asked Questions
What technologies does InSphero use?+
InSphero uses 30 technologies including Facebook Pixel, Google Analytics, Google Tag Manager.
What industry is InSphero in?+
InSphero operates in the Biotechnology industry.
Where is InSphero based?+
InSphero is headquartered in Switzerland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026